My Companies
Notification
Account
Log Out
Login
Cipla’s US subsidiary Invagen secured exclusive US licensing and supply of QL2107, Qilu’s pembrolizumab (Keytruda) biosimilar; Qilu handles development, regulatory filing and supply, while Cipla commercializes it, subject to approval. Context: second major portfolio-building partnership in roughly a year.
Cipla Signs Exclusive License With SBP For TQB2102 HER2 ADC
Cipla Receives VAI Classification For InvaGen New York Inspection
Cipla Receives Seven Form 483 Observations At Pithampur Facility
Cipla Receives US FDA Approval For Generic Advair Diskus Inhaler
Cipla Appoints Dinesh Jain Global CFO As Ashish Adukia Moves To Internal Role